UK markets open in 1 hour 57 minutes

Novozymes A/S (0Q4U.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
439.93-3.77 (-0.85%)
At close: 06:20PM BST
Full screen
Previous close443.70
Open435.00
BidN/A x N/A
AskN/A x N/A
Day's range433.80 - 441.70
52-week range288.50 - 441.70
Volume52,502
Avg. volume473,710
Market capN/A
Beta (5Y monthly)0.48
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est429.87
  • Globe Newswire

    Resolutions from the Extraordinary Shareholders’ Meeting 2024

    Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and amendment of the Articles of Association in accordance herewithElection of Jesper Brandgaard as Vice Chair of the Board of DirectorsElection of Lise Kaae, Kevin Lane and Kim Stratton as members of the Board of Directors Following the extraordinary shareholders’ meeting, the Board of Directors consists of the foll

  • Globe Newswire

    Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

    Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024Company announcement No. 07 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination") was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024. As previously announ

  • GlobeNewswire

    Legacy Novozymes delivers solid last full-year results

    Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality. COPENHAGEN, Denmark – February 1, 2024. In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before specia